La Matinale - 14-03-2023 - Portzamparc
HRS : Commande de Hympulsion – Acheter (1), obj. 28.8€ Cours: 20.6€ au 13/03/23MAUREL & PROM : Résultats et perspectives en dessous de nos attentes – Acheter (1), obj. 5.25€ Cours: 3.30€ au 13/03/23
VALBIOTIS : Dernière visite du dernier patient REVERSE-IT – Acheter (1), obj. 12.9€ Cours: 4.16€ au 13/03/23
Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.